HC Wainwright Issues Positive Forecast for CG Oncology (NASDAQ:CGON) Stock Price

CG Oncology (NASDAQ:CGON) had its price objective hoisted by analysts at HC Wainwright from $75.00 to $80.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 35.81% from the stock’s current price.

A number of other research analysts have also weighed in on CGON. Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a report on Wednesday, January 21st. Wedbush assumed coverage on shares of CG Oncology in a report on Thursday, December 11th. They issued an “outperform” rating and a $70.00 price target on the stock. Truist Financial raised their price target on shares of CG Oncology from $66.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. Morgan Stanley set a $93.00 price objective on shares of CG Oncology in a report on Friday, January 9th. Finally, Royal Bank Of Canada raised their target price on shares of CG Oncology from $61.00 to $73.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $69.00.

CG Oncology Price Performance

NASDAQ:CGON traded up $2.80 during trading hours on Friday, hitting $58.91. 515,889 shares of the company were exchanged, compared to its average volume of 1,161,141. CG Oncology has a 52-week low of $14.80 and a 52-week high of $60.00. The stock has a market capitalization of $4.75 billion, a price-to-earnings ratio of -28.88 and a beta of 1.32. The company’s 50 day moving average price is $50.03 and its 200-day moving average price is $41.84.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings data on Friday, February 27th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.10. The company had revenue of $2.32 million for the quarter. On average, equities analysts predict that CG Oncology will post -1.31 earnings per share for the current year.

Insider Activity at CG Oncology

In related news, Director James Mulay sold 11,145 shares of CG Oncology stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $52.47, for a total value of $584,778.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 7.40% of the stock is owned by company insiders.

Institutional Trading of CG Oncology

Several institutional investors have recently bought and sold shares of the business. Whittier Trust Co. of Nevada Inc. acquired a new stake in CG Oncology in the 4th quarter valued at $27,000. Winthrop Capital Management LLC acquired a new stake in shares of CG Oncology in the second quarter valued at about $38,000. Strengthening Families & Communities LLC purchased a new stake in shares of CG Oncology during the third quarter worth about $40,000. Comerica Bank lifted its stake in CG Oncology by 100.4% in the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after buying an additional 515 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its holdings in CG Oncology by 15.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock worth $85,000 after buying an additional 433 shares during the last quarter. 26.56% of the stock is owned by institutional investors and hedge funds.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.